Evidence-Based Treatment of Metastatic Gastric Cancer - Episode 2

Metastatic Gastric Cancer: Factors in Selecting Frontline Therapy

, , ,

EP. 1: Global Use of Frontline Therapy in Metastatic Gastric Cancer
Now Viewing
EP. 2: Metastatic Gastric Cancer: Factors in Selecting Frontline Therapy
EP. 3: Is Frontline IO Therapy Appropriate in Gastric Cancer?
EP. 4: Gastric Cancer: Global Perspectives on Maintenance Therapy
EP. 5: Switch Maintenance in Gastric Cancer: Results of JAVELIN Gastric 100
EP. 6: Metastatic Gastric Cancer: Identifying Disease Progression
EP. 7: Global Use of Second-Line Therapy in mGC
EP. 8: Chemotherapy + Ramucirumab as Second-Line Therapy in mGC
EP. 9: Later Lines of Therapy in Metastatic Gastric Cancer
EP. 10: Emerging Biomarkers in Metastatic Gastric Cancer
EP. 11: Metastatic Gastric Cancer: Promising Frontline Trials
EP. 12: Gastric Cancer: Frontline Checkpoint Inhibitor Trials
EP. 13: Metastatic Gastric Cancer: Novel Agents Targeting FGF
EP. 14: Metastatic Gastric Cancer: Promising Second-Line Trials
EP. 15: Metastatic Gastric Cancer: Promising Later-Line Trials
EP. 16: Perioperative Strategies in Metastatic Gastric Cancer
EP. 17: Metastatic Gastric Cancer: Recent Advances and Future Directions

Transcript:

Related Content:

Evidence-Based Treatment of Metastatic Gastric CancerGastrointestinal Cancer
State of Science Summit: Gastrointestinal Cancer - Chaired by: Tanios Bekaii-Saab, MD and Darshil Shah, MD, MPH
The OncFive: Top Oncology Articles for the Week 9/22
ODAC Votes Against Risk:Benefit Profile of Frontline Anti–PD-1 Therapy in Metastatic/Unresectable ESCC With a PD-L1 Expression Under 1